Voronoi to strengthen AI-driven open innovation

South Korea’s biotechnology startup Voronoi Inc. announced on Monday that it is intensifying its artificial intelligence (AI)-driven new drug development open innovation business.

The company filed a patent related to AI technology for lead optimization in its pipeline.

"Collaborative research companies can swiftly identify candidate substances with high selectivity and blood-brain barrier penetration using the Voronoi AI platform," said Kim Hyun-Tae, the head of Voronoi's management division. "Through open innovation, Voronoi aims to secure pipeline shares for increased profitability while expanding its research scope."

Voronoi is launching a new business of expanding its pipeline through AI-driven new drug development and open innovation with global pharmaceutical companies. The multidimensional validation of its AI new drug development platform, which has been refined using the largest experimental dataset in South Korea from the early stages of its founding, has been recently completed.

Through the synthesis of over 4,000 substances per year and animal experiments, Voronoi has amassed millions of experimental data points. It has also simultaneously pursued patent applications for substances at a level comparable to the top ten in the world in the same field.

Building on this foundation, it has developed the platform called Voronomix, which integrates AI into every aspect of the new drug development process, including substance discovery, patent assessment, synthesis feasibility analysis, drug efficacy improvement diagnosis and candidate substance optimization.

Write to Yoo-Rim Kim at youforest@hankyung.com